^
    Back
    Association details:
    Biomarker:BRAF G464
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

    Published date:
    08/08/2023
    Excerpt:
    In NADIM trials, pathogenic or likely pathogenic genetic alterations in the BRAF gene occurred in 4.35% of the patients (n=4; p.L597Q, p.G469V, p.G464, p.V600E). BRAF pathogenic mutations were significantly enriched in tumors showing pathological complete response after neoadjuvant treatment with chemo-immunotherapy.
    Secondary therapy:
    Chemotherapy
    Test:
    Oncomine™ Pan-Cancer Cell-Free Assay